AstraZeneca wins kudos for pipeline turnaround in a new ranking of the top 10 R&D players in the biopharma world
Two years ago, after the first leg of AstraZeneca’s highly touted MYSTIC study failed, with Imfinzi and tremelimumab flunking a major test in lung cancer, the pharma giant’s R&D group looked like they were about to be put on life support. Today, they’re being hailed as the most innovative and inventive major player in drug development today.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 65,000+ biopharma pros reading Endpoints daily — and it's free.